Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.74 |
| ▸ | CFTR | P13569 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.67 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.59 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23001307 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL29365020 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL22469940 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL27318281 | 0.92 | NLRP3 (0.86) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL25144914 | 0.90 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL28687390 | 0.87 | NLRP3 (1.00) | NLRP3PTPN1MEN1KMT2ADUSP22 | |
| SCHEMBL28687393 | 0.87 | NLRP3 (1.00) | NLRP3PTPN1MEN1KMT2ADUSP22 | |
| SCHEMBL919042 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 | |
| SCHEMBL1881897 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 | |
| SCHEMBL1326698 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | claimed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | claimed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | claimed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | claimed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | claimed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | claimed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | claimed |
| CN-114728077-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114728076-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | claimed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | claimed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | KULKARNI ASHISH (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| EP-3941897-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | Integrated Nanotherapeutics Inc. (CA) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021185912-A1 | METHOD FOR THE TREATMENT NLRP3-ASSOCIATED DISEASES | SOFTHALE NV (BE) | 2021-09-23 | — | — | WO | disclosed |
| US-20210077582-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF ANTI-PD-1 ANTIBODY IMMUNOTHERAPY | DUKE UNIVERSITY (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2020191477-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | NLRP3 4751/4885PTPN1 1815/4885CFTR 4188/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | NLRP3 4244/4885PTPN1 1566/4885CFTR 4435/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | NLRP3 4863/4885PTPN1 1919/4885CFTR 3857/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | NLRP3 4808/4885PTPN1 2562/4885CFTR 3876/4885 |
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | NLRP3, NLRP1, IL1B | NLRP3 1/4885PTPN1 1853/4885CFTR 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.